Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury.
Diabetes increases the incidence of cardiovascular disease as well as the complications of myocardial infarction. Studies using animal models of diabetes have demonstrated that the metabolic alterations occurring at the myocyte level may contribute to the severity of ischemic injury in diabetic hearts. Of the several mechanisms being investigated to understand the pathogenesis of diabetic complications, the increased metabolism of glucose via the polyol pathway has received considerable attention. Deviant metabolic regulation due to increased flux through aldose reductase in diabetic hearts may influence the ability of the myocardium to withstand ischemia insult. To determine if aldose reductase inhibition improves tolerance to ischemia, hearts from acute type I diabetic and nondiabetic control rats were isolated and retrograde perfused. Each group was exposed to 1 micromol/l zopolrestat, a specific inhibitor of aldose reductase, for 10 min, followed by 20 min of global ischemia and 60 min of reperfusion in the absence of zopolrestat. Zopolrestat reduced sorbitol levels before ischemia in diabetic hearts. The cytosolic redox state (NADH/NAD+), as measured by lactate-to-pyruvate ratios, was significantly lowered under baseline, ischemic, and reperfusion conditions in diabetic hearts perfused with zopolrestat. In these diabetic hearts, ATP was significantly higher in zopolrestat hearts during ischemia, as were phosphocreatine and left ventricular-developed pressure on reperfusion. Zopolrestat provided similar metabolic and functional benefits in nondiabetic hearts. Creatine kinase release was reduced by approximately 50% in both nondiabetic and diabetic hearts treated with zopolrestat. These data indicate that inhibition of aldose reductase activity preserves high-energy phosphates, maintains a lower cytosolic NADH/NAD+ ratio, and markedly protects both diabetic and nondiabetic hearts during ischemia and reperfusion.
Ramasamy
R
R
Department of Internal Medicine, University of California, Davis 95616, USA.
Oates
P J
PJ
Schaefer
S
S
D000255:Adenosine Triphosphate / Q000378:metabolism; D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D000818:Animals; D052160:Benzothiazoles; D001786:Blood Glucose / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000503:physiopathology*; D004734:Energy Metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005632:Fructose / Q000378:metabolism; D006863:Hydrogen-Ion Concentration; D007773:Lactates / Q000378:metabolism; D009682:Magnetic Resonance Spectroscopy; D017202:Myocardial Ischemia / Q000503:physiopathology*; D009206:Myocardium / Q000378:metabolism; D009243:NAD / Q000378:metabolism; D010793:Phthalazines / Q000494:pharmacology*; D011773:Pyruvates / Q000378:metabolism; D051381:Rats; D011913:Rats, Inbred BB; D015427:Reperfusion Injury / Q000503:physiopathology / Q000517:prevention & control*; D013012:Sorbitol / Q000378:metabolism; D013844:Thiazoles / Q000494:pharmacology*
D052160:Benzothiazoles; D001786:Blood Glucose; D004791:Enzyme Inhibitors; D007773:Lactates; D010793:Phthalazines; D011773:Pyruvates; D013844:Thiazoles; D009243:NAD; C067172:zopolrestat; D005632:Fructose; D013012:Sorbitol; D000255:Adenosine Triphosphate; D000449:Aldehyde Reductase